12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Deals

Isis Pharmaceuticals, Pfizer deal

Isis will receive a $1.3 million milestone payment from Pfizer triggered by the pharma's decision to advance EXC 001 ( PF-06473871) into Phase II testing. Pfizer gained rights to EXC...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >